[1] THEODOROPOULOU M,STALLA G K.Somatostatin receptors:from signaling to clinical practice[J].Front Neuroendocrinol,2013,34(3):228-252.
[2] REUBI J C,SCHONBRUNN A.Illuminating somatostatin analog action at neuroendocrine tumor receptors[J].Trends Pharmacol Sci,2013,34(12):676-688.
[3] PENG Y,DENG L,DING Y,et al.Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding,internalization and activation[J].PLoS One,2014,9(2):e89932.
[4] WANG L,TANG K,ZHANG Q,et al.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors[J].Biomed Res Int,2013,2013(6):102819.
[5] SUNL C,COY D H.Somatostatin receptor-targeted anti-cancer therapy[J].Curr Drug Deliv,2011,8(1):2-10.
[6] KESKIN O,YALCIN S.Areview of the use of somatostatin analogs in oncology[J].Onco Targets Ther,2013,6(3):471-483.
[7] 张菁华,张文侠.生长抑素在肿瘤临床的研究与应用现状[J].现代肿瘤医学,2011,19(9):1890-1895.
[8] 曾希志,姚榛祥.生长抑素类似物的抗肿瘤作用机制[J].肿瘤,2001,21(4):307-309.
[9] 刘文斌,李建生.生长抑素抗肿瘤机制研究进展[J].安徽医药,2005,9(1):7-9.
[10] CHALABI M,DULUC C,CARON P,et al.Somatostatin analogs:does pharmacology impact antitumor efficacy?[J].Trends Endocrinol Metab,2014,25(3):115-127.
[11] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
[12] BYERS L A,RUDIN C M.Small cell lung cancer:where do we go from here?[J].Cancer,2015,121(5):664-672.
[13] 余英豪,王丽,刘伟.肺神经内分泌肿瘤的病理学诊断要点及研究进展[J].临床与实验病理学杂志,2013,29(2):119-121.
[14] FISSELER-ECKHOFF A,DEMES M.Neuroendocrine tumors of the lung[J].Cancers(Basel),2012,4(3):777-798.
[15] RIGHI L,VOLANTE M,TAVAGLIONE V,et al.Somatostatin receptor tissue distribution in lung neuroendocrine tumours:a clinicopathologic and immunohistochemical study of 218‘clini-cally aggressive’cases[J].Ann Oncol,2010,21(3):548-555.
[16] SLOTMAN B J,Van TINTEREN H,PRAAG J O,et al.Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J].Lancet,2015,385(9962):36-42.
[17] 张赫男,刘云鹏.局限期小细胞肺癌治疗的研究进展[J].中南大学学报:医学版,2013,38(8):857-862.
[18] BRENNER S,KLAMETH L,RIHA J,et al.Specific expression of OATPs in primary small cell lung cancer(SCLC)cells as novel biomarkers for diagnosis and therapy[J].Cancer Lett,2015,356(2):517-524.
[19] TSUTA K,WISTUBA I I,MORAN C A,et al.Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung[J].Pathol Res Pract,2012,208(8):470-474.
[20] 李贵平,张辉,池晓华,等.多肽受体介导的放射性核素靶向治疗的研究进展[J].放射免疫学杂志,2010,23(3):308-312.
[21] BISON S M,KONIJNENBERG M W,MELIS M,et al.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs:focus on future developments[J].Clin Transl Imaging,2014,2(1):55-66.
[22] BEARZ A,LLESHI A,PERIN T,et al.Small cell lung cancer in an elderly patient:efficacy of somatostatin analog treatment,a case report[J].Onkologie,2011,34(3):117-120.
[23] ZAROGOULIDIS K,ELEFTHERIADOU E,KONTAKIOTIS T,et al.Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients[J].Lung Cancer,2012,76(1):84-88. |
